<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400163</url>
  </required_header>
  <id_info>
    <org_study_id>MB130-045 A</org_study_id>
    <nct_id>NCT03400163</nct_id>
  </id_info>
  <brief_title>A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects,
      pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with
      Non-alcoholic Steatohepatitis (NASH)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2015</start_date>
  <completion_date type="Actual">June 19, 2017</completion_date>
  <primary_completion_date type="Actual">January 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent hepatic fat fraction (%) by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>From Day 1 to Day 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and AEs leading to discontinuation</measure>
    <time_frame>From first dose to date of last dose plus 100 days (up to 212 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with marked laboratory abnormalities</measure>
    <time_frame>From first dose to date of last dose plus 100 days (up to 212 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant ECG abnormalities</measure>
    <time_frame>From first dose to date of last dose plus 100 days (up to 212 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant vital sign abnormalities</measure>
    <time_frame>From first dose to date of last dose plus 100 days (up to 212 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with injection site reactions</measure>
    <time_frame>From first dose to date of last dose plus 100 days (up to 212 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change from baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)</measure>
    <time_frame>From Day 1 to Day 112</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112</measure>
    <time_frame>From Day 1 to Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with positive Anti-BMS-986036 Antibody response at Day 142</measure>
    <time_frame>From Day 1 to Day 142</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with positive Anti-FGF21 Antibody response at Day 142</measure>
    <time_frame>From Day 1 to Day 142</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Treatment Group D:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group E:</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986036</intervention_name>
    <description>BMS-986036 20 mg QD</description>
    <arm_group_label>Treatment Group D:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD</description>
    <arm_group_label>Treatment Group E:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female between 21 and 75 years old

          -  Body Mass Index (BMI) of 25 or more

        Exclusion Criteria:

          -  Chronic Liver disease other than NASH

          -  Uncontrolled diabetes

          -  Any major surgery within 6 weeks of screening

          -  Unable to self-administer under the skin injections

          -  Any bone trauma, fracture or bone surgery within 8 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <disposition_first_submitted>January 17, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 17, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 19, 2018</disposition_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First Line Therapy</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

